Biological samples, or specimens, are widely used in R&D for drug development and diagnostics assay development. As the COVID-19 pandemic broke through, many samples have been colelcted around the world: nasal or nasopharyngeal swabs, blood and derivatives, respiratory tracts biopsies, for the different variants of SARS-CoV-2, including Alpha, Epsilon, Delta, Omicron. Because of the variety of samples that can exist, vaccination status, variant, age and other clinical requirements, it can be difficult to find the right source.
This is why Labtoo developed a tailor-made service to support Labs, Biotechs, Medtech, and Pharma companies in their procurement of COVID-19 samples.
Labtoo can be mandated in a fully customized mission to look for any type of COVID-19 biospecimen, fresh swabs, frozen swabs, FFPE tissues, or blood samples. We work with hospitals, biobanks, and CROs to look for the best samples according to specific needs, with all regulatory and legal requirements handled.
As we do not use a catalog solution, our team will identify samples already in sample biobanks or collections, if possible, and compatible with the requirements of the project. A prospective clinical collection can also be started when necessary.
